
Opinion|Videos|July 2, 2024
RSV Vaccine Efficacy in Pregnancy
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.
Advertisement
Episodes in this series

- What were the key results from the
MATISSE trial regarding the safety and efficacy of the non-adjuvanted vaccine in pregnant women?
- Efficacy in preventing severe RSV in infants
- Adverse effects in maternal and infant subjects
- Trial limitations: no high-risk pregnancies
Advertisement
Related to this article

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
Navigating State Vaccine Regulations: Challenges for Community Pharmacies
5



